INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,203,110 | +106.5% | 138,282 | +151.0% | 0.00% | – |
| Q2 2023 | $3,488,488 | -90.7% | 55,093 | -92.0% | 0.00% | -100.0% |
| Q1 2023 | $37,491,078 | -5.7% | 692,356 | -7.8% | 0.01% | -22.2% |
| Q4 2022 | $39,746,254 | +210.0% | 751,063 | +172.6% | 0.01% | +200.0% |
| Q3 2022 | $12,820,000 | -58.6% | 275,532 | -49.2% | 0.00% | -62.5% |
| Q2 2022 | $30,933,000 | -29.1% | 541,931 | -24.0% | 0.01% | -11.1% |
| Q1 2022 | $43,635,000 | -16.8% | 713,132 | -28.8% | 0.01% | -18.2% |
| Q4 2021 | $52,419,000 | +7.6% | 1,001,516 | -23.4% | 0.01% | +10.0% |
| Q3 2021 | $48,739,000 | -29.3% | 1,307,365 | -22.6% | 0.01% | -37.5% |
| Q2 2021 | $68,928,000 | +25.8% | 1,688,592 | +4.5% | 0.02% | +23.1% |
| Q1 2021 | $54,807,000 | +2.9% | 1,615,306 | -3.6% | 0.01% | -7.1% |
| Q4 2020 | $53,287,000 | +43.0% | 1,675,686 | +15.4% | 0.01% | +40.0% |
| Q3 2020 | $37,259,000 | +65.5% | 1,452,062 | +65.5% | 0.01% | +11.1% |
| Q2 2020 | $22,517,000 | +221.4% | 877,160 | +92.4% | 0.01% | +200.0% |
| Q1 2020 | $7,006,000 | -92.5% | 455,787 | -83.3% | 0.00% | -92.7% |
| Q4 2019 | $93,543,000 | +711.4% | 2,726,414 | +76.6% | 0.04% | +720.0% |
| Q3 2019 | $11,529,000 | +56.4% | 1,543,421 | +171.8% | 0.01% | +25.0% |
| Q2 2019 | $7,371,000 | +175.9% | 567,848 | +158.7% | 0.00% | +100.0% |
| Q1 2019 | $2,672,000 | -81.4% | 219,472 | -82.6% | 0.00% | -75.0% |
| Q4 2018 | $14,384,000 | -24.2% | 1,262,933 | +44.4% | 0.01% | -11.1% |
| Q3 2018 | $18,979,000 | -22.9% | 874,593 | -37.2% | 0.01% | -18.2% |
| Q2 2018 | $24,613,000 | -1.2% | 1,392,924 | +17.7% | 0.01% | -15.4% |
| Q1 2018 | $24,902,000 | +715.1% | 1,183,027 | +460.6% | 0.01% | +550.0% |
| Q4 2017 | $3,055,000 | +82.5% | 211,038 | +99.0% | 0.00% | +100.0% |
| Q3 2017 | $1,674,000 | -90.5% | 106,032 | -92.6% | 0.00% | -93.3% |
| Q2 2017 | $17,684,000 | +32.0% | 1,423,793 | +72.7% | 0.02% | +25.0% |
| Q1 2017 | $13,394,000 | -30.8% | 824,227 | -35.7% | 0.01% | -36.8% |
| Q4 2016 | $19,356,000 | +991.1% | 1,282,682 | +1002.0% | 0.02% | +850.0% |
| Q3 2016 | $1,774,000 | +99.8% | 116,397 | +408.9% | 0.00% | +100.0% |
| Q2 2016 | $888,000 | +226.5% | 22,871 | +133.6% | 0.00% | – |
| Q1 2016 | $272,000 | -36.4% | 9,791 | +23.0% | 0.00% | – |
| Q4 2015 | $428,000 | -80.2% | 7,957 | -85.3% | 0.00% | -100.0% |
| Q3 2015 | $2,164,000 | +824.8% | 54,043 | +637.0% | 0.00% | – |
| Q2 2015 | $234,000 | -92.2% | 7,333 | -94.2% | 0.00% | -100.0% |
| Q1 2015 | $3,002,000 | – | 125,723 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |